Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.55
+0.23003.14%
Post-market: 7.45-0.1000-1.32%19:30 EDT
Volume:1.73M
Turnover:13.30M
Market Cap:683.75M
PE:-3.13
High:7.91
Open:7.58
Low:7.54
Close:7.32
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:0.83
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:13.68
PE(LYR):-2.50

Loading ...

Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors

MT Newswires Live
·
Jun 24

Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375

Dow Jones
·
Jun 24

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

TIPRANKS
·
Jun 24

Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors

Reuters
·
Jun 24

Verastem - VS-7375 Shows Anti-Tumor Activity With Anti-Egfr Therapy or Standard Chemotherapy

THOMSON REUTERS
·
Jun 24

Verastem - Co and Erasca Announce Intent to Evaluate VS-7375 With Eras-15 in Kras G12d Tumors

THOMSON REUTERS
·
Jun 24

VS-7375 Demonstrates Clinical Activity With a Favorable Safety and Tolerability Profile in Target-D 101 Phase 1/2 Clinical Trial in Patients With Advanced Kras G12d-Mutated Solid Tumors

THOMSON REUTERS
·
Jun 24

Verastem - VS-7375 Safety Profile Mainly Low-Grade Gi Events That Decrease After Cycle 1

THOMSON REUTERS
·
Jun 24

Verastem price target lowered to $8 from $15 at Jefferies

TIPRANKS
·
Jun 24

Verastem Is Maintained at Buy by Jefferies

Dow Jones
·
Jun 23

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron

Reuters
·
Jun 17

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and ClearPoint Neuro (CLPT)

TIPRANKS
·
Jun 17

Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial

TIPRANKS
·
Jun 17

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

TIPRANKS
·
Jun 17

BUZZ-Verastem rises as combo therapy shows early benefit in pancreatic cancer

Reuters
·
Jun 17

Verastem says RAMP 205 trial shows 52% response rate for avutometinib-defactinib combo in first-line metastatic pancreatic cancer

Reuters
·
Jun 17

Verastem Oncology Announces Positive Updated Results From Ramp 205 Evaluating Avutometinib Plus Defactinib in Combination With Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jun 17

Verastem - Reports 86% Overall Survival Rate at 6 Months as of June 5, 2026

THOMSON REUTERS
·
Jun 17

Verastem - No New Safety Signals Observed in Ramp 205 Trial

THOMSON REUTERS
·
Jun 17

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

TIPRANKS
·
Jun 17